학술논문
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019.
Document Type
Article
Author
Bloch, Evan M; Focosi, Daniele; Shoham, Shmuel; Senefeld, Jonathon; Tobian, Aaron A R; Baden, Lindsey R; Tiberghien, Pierre; Sullivan, David J; Cohn, Claudia; Dioverti, Veronica; Henderson, Jeffrey P; So-Osman, Cynthia; Juskewitch, Justin E; Razonable, Raymund R; Franchini, Massimo; Goel, Ruchika; Grossman, Brenda J; Casadevall, Arturo; Joyner, Michael J; Avery, Robin K
Source
Subject
*COVID-19
*IMMUNOGLOBULINS
*IMMUNIZATION
*IMMUNOCOMPROMISED patients
*MONOCLONAL antibodies
*TREATMENT duration
*CONVALESCENT plasma
*
*
*
*
*
*
Language
ISSN
1058-4838
Abstract
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective. [ABSTRACT FROM AUTHOR]